Menarini
Menarini Group, a prominent player in the pharmaceutical industry, is headquartered in Florence, Italy. Founded in 1886, the company has established a strong presence across Europe, Asia, and the Americas, focusing on research, development, and the manufacturing of innovative healthcare solutions. Specialising in prescription pharmaceuticals, over-the-counter products, and diagnostics, Menarini is recognised for its commitment to quality and patient care. The company’s core offerings include therapeutic areas such as oncology, cardiology, and infectious diseases, distinguished by their efficacy and safety profiles. With a rich history of milestones, Menarini has achieved significant market position, consistently ranking among the top pharmaceutical companies in Italy. Its dedication to advancing medical science and improving patient outcomes underscores its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Menarini's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Menarini's score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Menarini's reported carbon emissions
In 2023, Menarini reported total carbon emissions of approximately 1,239,770 kg CO2e, comprising 100,390 kg CO2e from Scope 1, 26,250 kg CO2e from Scope 2, and about 1,125,130 kg CO2e from Scope 3 emissions. This represents a slight decrease in total emissions compared to 2022, where total emissions were approximately 1,295,640 kg CO2e, with Scope 1 at 47,200 kg CO2e, Scope 2 at 21,970 kg CO2e, and Scope 3 at 1,275,970 kg CO2e. Menarini has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. However, the company continues to monitor and report its emissions across all three scopes, demonstrating a commitment to transparency in its climate impact. As a pharmaceutical company headquartered in Italy, Menarini is positioned within an industry increasingly focused on sustainability and reducing carbon footprints.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Menarini is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
